Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Accenture
Julphar
Johnson and Johnson
Daiichi Sankyo
Covington
Chubb
Dow
AstraZeneca

Generated: August 16, 2018

DrugPatentWatch Database Preview

SANCTURA XR Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Sanctura Xr, and when can generic versions of Sanctura Xr launch?

Sanctura Xr is a drug marketed by Allergan and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has fifteen patent family members in eleven countries.

The generic ingredient in SANCTURA XR is trospium chloride. There are sixteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.

Drug patent expirations by year for SANCTURA XR
Synonyms for SANCTURA XR
(1alpha,5alpha)-3beta-[(Hydroxydiphenylacetyl)oxy]spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium]
[(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate chloride
[(1S,5R)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride
[(1S,5R)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-oxidanyl-2,2-diphenyl-ethanoate chloride
1001323-19-8
10405-02-4
1E6682427E
2-hydroxy-2,2-diphenylacetic acid [(1S,5R)-3-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]yl] ester chloride
3-((hydroxydiphenylacetyl)oxy)-spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium chloride
3alpha-Hydroxyspiro(1alphah,5alphah-nortropane-8,1'-pyrrolidinium) benzilate
3alpha-Hydroxyspiro(1alphaH,5alphaH-nortropane-8,1'-pyrrolidinium) chloride benzilate
405T024
47608-32-2
8-alpha-Benziloyloxy-6,10-ethano-5-azoniaspiro(4.5)decane chloride
A800884
AB0000782
AB01274814_02
AB01274814-01
AB2000646
AC-4235
AC1NR4ST
AKOS015833209
AM84314
API0004533
AS Xvii
Azoniaspiro Compound XVII
Azoniaspiro(3-alpha-benziloyloxy-nortropan-8,1'-pyrrolidine)-chloride
B-1868
BC209629
BCP0726000291
CAS-10405-02-4
CHEBI:32270
CHEMBL1888176
CHEMBL3084748
Chlorure de trospium
Chlorure de trospium [INN-French]
Cloruro de trospio
Cloruro de trospio [INN-Spanish]
CS-2572
DB00209
DSSTox_CID_3724
DSSTox_GSID_23724
DSSTox_RID_77166
DTXSID6048337
DTXSID7023724
EINECS 233-875-4
FT-0636699
HMS3656C16
HY-B0461
IP631
Keptan
MFCD00865254
MolPort-005-935-494
MolPort-046-033-481
NCGC00167438-01
NCGC00167438-02
Relaspium
RVCSYOQWLPPAOA-QKYUOBHYSA-M
s2549
Sanctura
Santura
SCHEMBL119810
SCHEMBL13836646
SCHEMBL2447242
SCHEMBL25785
Spasmex
Spasmo 3
Spasmo-lyt
Spiro (8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-((hydroxydiphenylacetyl)oxy)-, chloride, (1alpha, 3beta, 5alpha)
Spiro(1-alpha-H,5-alpha-H-nortropane-8,1'-pyrrolidinium), 3-alpha-hydroxy-, chloride, benzilate
Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium, 3-((hydroxydiphenylacetyl)oxy)-, chloride, (1alpha,3beta,5alpha)-
Spiro[8azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(hydroxydiphenylacetyl)oxy]-, chloride, (1, 3, 5);Spiro[8azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(hydroxydiphenylacetyl)oxy]-, chloride, (1, 3, 5)
ST24050330
T4Y8ORK057
Tox21_112442
Tox21_112442_1
Trospii chloridum
Trospii chloridum [INN-Latin]
Trospium
Trospium (chloride)
Trospium cation
trospium chloride
Trospium chloride (Sanctura)
Trospium chloride [USAN:USP:INN:BAN:JAN]
Trospium Cl
Trospiumchlorid
UNII-1E6682427E
UNII-T4Y8ORK057
Uraplex
W-108827
ZINC100016084
ZINC100371992
ZINC12503068

US Patents and Regulatory Information for SANCTURA XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for SANCTURA XR
Drugname Dosage Strength RLD Date
➤ Subscribe Extended-release Capsules 60 mg ➤ Subscribe ➤ Sign Up

Premature patent expiration for: SANCTURA XR

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
➤ Sign Up SANCTURA XR ➤ Sign Up

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Teva
McKesson
US Department of Justice
Fish and Richardson
AstraZeneca
Argus Health
Daiichi Sankyo
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.